Karyopharm Therapeutics Investor Presentation — May 2022

Document content

1 ©2022 KARYOPHARM THERAPEUTICS INC.

May 2022A Commercial -Stage

Novel Cancer Therapies2 ©2022 KARYOPHARM THERAPEUTICS INC. Forward -looking Statements and Other Important Information

This presentation contains forward -looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding

Karyopharm's guidance onits2022 netproduct revenue and2022 non-GAAP research anddevelopment andselling, general andadministrative expenses ;Karyopharm’s expected cash runway ;the

ability ofselinexor oreltanexor totreat patients with multiple myeloma, diffuse large B-celllymphoma, solid tumors andother diseases ;andexpectations related tofuture clinical development and

potential regulatory submissions ofselinexor andeltanexor .Such statements aresubject tonumerous important factors, risks anduncertainties, many ofwhich arebeyond Karyopharm's control, that

may cause actual events orresults todiffer materially from Karyopharm's current expectations .Forexample, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO ;

thatregulators willgrant confirmatory approval intheEuropean Union based ontheBOSTON study inadult patients with multiple myeloma ;orthatanyofKaryopharm’s drug candidates, including

selinexor and eltanexor, willsuccessfully complete necessary clinical development phases orthatdevelopment ofanyofKaryopharm’s drug candidates willcontinue .Further, there canbeno

guarantee thatanypositive developments inthedevelopment orcommercialization ofKaryopharm’s drug candidate portfolio willresult instock price appreciation .Management’s expectations and,

therefore, anyforward -looking statements inthispress release could also beaffected byrisks anduncertainties relating toanumber ofother factors, including thefollowing :theriskthattheCOVID -19

pandemic could disrupt Karyopharm’s business more severely than itcurrently anticipates, including bynegatively impacting sales ofXPOVIO, interrupting ordelaying research anddevelopment

efforts, impacting theability toprocure sufficient supply forthedevelopment andcommercialization ofselinexor orother product candidates, delaying ongoing orplanned clinical trials, impeding the

execution ofbusiness plans, planned regulatory milestones andtimelines, orinconveniencing patients ;theadoption ofXPOVIO inthecommercial marketplace, thetiming andcosts involved in

commercializing XPOVIO oranyofKaryopharm’s drug candidates thatreceive regulatory approval ;theability toobtain and retain regulatory approval ofXPOVIO oranyofKaryopharm’s drug

candidates thatreceive regulatory approval ;Karyopharm's results ofclinical trials andpreclinical studies, including subsequent analysis ofexisting data andnew data received from ongoing andfuture